Stock MOLN MOLECULAR PARTNERS AG
Add to a list
To use this feature you must be a member
Log inSign up

All News Molecular Partners AG

Equities

MOLN

CH0256379097

Market Closed - Swiss Exchange
Other stock markets
 11:30:41 2024-05-31 am EDT 		5-day change 1st Jan Change
3.4 CHF -2.86% Intraday chart for Molecular Partners AG +0.29% -1.16%
02:00pm Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024 CI
Apr. 29 Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Molecular Partners : Corporate Presentation - June 2024
PU
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
AQ
Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024
CI
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
GL
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action 
GL
Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action
CI
Molecular Partners : Annual General Meeting Minutes
PU
Life Science Cares Launches in Switzerland
GL
Molecular Partners : statement regarding Passive Foreign Investment Company status
PU
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
GL
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
AQ
Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement
AQ
Molecular Partners Publishes Invitation to Annual General Meeting 2024
GL
Molecular Partners Publishes Invitation to Annual General Meeting 2024
AQ
Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024
Molecular Partners Swings to Loss in FY23; Revenue Down
MT
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
GL
Molecular Partners AG Reports Earnings Results for the Full Year Ended December 31, 2023
CI
US Court Dismisses Putative Class Action Against Molecular Partners
MT
Molecular Partners Announces Dismissal of Class Action Lawsuit
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MOLN Stock
  4. News Molecular Partners AG